Skip to main content
Neal Lindeman, MD, Pathology, Boston, MA

NealILindemanMD

Pathology Boston, MA

Chemical Pathology, Molecular Genetics, Pulmonary Pathology, Anatomic Pathology

Associate Professor, Pathology-Brigham & Women's Hospital, Harvard Medical School

Dr. Lindeman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lindeman's full profile

Already have an account?

  • Office

    75 Francis Street Amory 3
    Brigham And Womens Hospital Department Of Pathology
    Boston, MA 02115
    Phone+1 617-732-6790

Education & Training

  • University of California San Francisco School of Medicine
    University of California San Francisco School of MedicineResidency, 1994 - 1999
  • University of Rochester School of Medicine and Dentistry
    University of Rochester School of Medicine and DentistryClass of 1994

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1996 - Present
  • NY State Medical License
    NY State Medical License 2022 - 2026
  • MA State Medical License
    MA State Medical License 2000 - 2023
  • American Board of Pathology Anatomic Pathology & Clinical Pathology
  • American Board of Pathology Molecular Genetic Pathology

Publications & Presentations

PubMed

Press Mentions

  • Upcoming Lung Cancer Molecular Testing Guidelines Address 7 Questions
    Upcoming Lung Cancer Molecular Testing Guidelines Address 7 QuestionsAugust 28th, 2024
  • Specialists Launch Revised Lung Most Cancers Testing Pointers
    Specialists Launch Revised Lung Most Cancers Testing PointersAugust 23rd, 2024
  • International Lung Cancer Experts Seek Public Comments on Updated Molecular Testing Guideline to Improve Patient Selection and Targeted Therapies
    International Lung Cancer Experts Seek Public Comments on Updated Molecular Testing Guideline to Improve Patient Selection and Targeted TherapiesAugust 22nd, 2024
  • Join now to see all